Dr. James P. Krainson

Pulmonary Medicine | Sleep Medicine
12600 Sw 120th St, Suite 117, 
Miami, FL 
12600 Sw 120th St, Suite 117, 
Miami, FL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

James Krainson is a Pulmonary Medicine specialist and a Sleep Medicine provider in Miami, Florida. His top areas of expertise are Obstructive Sleep Apnea, Asbestosis, Severe Acute Respiratory Syndrome (SARS), and Narcolepsy.

His clinical research consists of co-authoring 5 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Pulmonary Medicine
Sleep Medicine
Licenses
Internal Medicine in FL
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D

Locations

12600 Sw 120th St, Suite 117, Miami, FL 33186

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

A 52-week, Randomised, Double-blind, Double-dummy, Parallel Group, Multi-centre, Non-inferiority Study Assessing Exacerbation Rate, Additional Measures of Asthma Control and Safety in Adult and Adolescent Severe Asthmatic Participants With an Eosinophilic Phenotype Treated With GSK3511294 Compared With Mepolizumab or Benralizumab
A 52-week, Randomised, Double-blind, Double-dummy, Parallel Group, Multi-centre, Non-inferiority Study Assessing Exacerbation Rate, Additional Measures of Asthma Control and Safety in Adult and Adolescent Severe Asthmatic Participants With an Eosinophilic Phenotype Treated With GSK3511294 Compared With Mepolizumab or Benralizumab
Enrollment Status: Completed
Publish Date: October 15, 2025
Intervention Type: Biological, Drug, Device
Study Drugs: Depemokimab, Mepolizumab, Benralizumab
Study Phase: Phase 3
A Multi-center, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of Mepolizumab 100 mg SC as add-on Treatment in Participants With COPD Experiencing Frequent Exacerbations and Characterized by Eosinophil Levels (Study 208657)
A Multi-center, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of Mepolizumab 100 mg SC as add-on Treatment in Participants With COPD Experiencing Frequent Exacerbations and Characterized by Eosinophil Levels (Study 208657)
Enrollment Status: Completed
Publish Date: August 15, 2025
Intervention Type: Drug, Biological
Study Drug: Mepolizumab
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled, Multiple Rising Oral Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-994 in Patients With Narcolepsy With or Without Cataplexy (Narcolepsy Type 1 or Narcolepsy Type 2)
A Randomized, Double-Blind, Placebo-Controlled, Multiple Rising Oral Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-994 in Patients With Narcolepsy With or Without Cataplexy (Narcolepsy Type 1 or Narcolepsy Type 2)
Enrollment Status: Terminated
Publish Date: October 29, 2024
Intervention Type: Drug
Study Drug: TAK-994
Study Phase: Phase 2
A Randomized, Double-blind, Placebo-Controlled, Phase 2/3 Study to Evaluate the Efficacy and Safety of LY3819253 and LY3832479 in Participants With Mild to Moderate COVID-19 Illness
A Randomized, Double-blind, Placebo-Controlled, Phase 2/3 Study to Evaluate the Efficacy and Safety of LY3819253 and LY3832479 in Participants With Mild to Moderate COVID-19 Illness
Enrollment Status: Completed
Publish Date: April 11, 2024
Intervention Type: Drug
Study Drugs: Bamlanivimab, Etesevimab
Study Phase: Phase 2/Phase 3
A Dose-Blind Extension Study With Double-blind, Placebo-Controlled, Randomized Withdrawal Period to Evaluate the Safety and Explore the Pharmacokinetics and Pharmacodynamics of TAK-994 in Adults With Narcolepsy With Cataplexy (Narcolepsy Type 1)
A Dose-Blind Extension Study With Double-blind, Placebo-Controlled, Randomized Withdrawal Period to Evaluate the Safety and Explore the Pharmacokinetics and Pharmacodynamics of TAK-994 in Adults With Narcolepsy With Cataplexy (Narcolepsy Type 1)
Enrollment Status: Terminated
Publish Date: December 26, 2023
Intervention Type: Drug
Study Phase: Phase 2
A Phase III Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ensifentrine Over 24 Weeks in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
A Phase III Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ensifentrine Over 24 Weeks in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
Enrollment Status: Completed
Publish Date: October 16, 2023
Intervention Type: Drug
Study Drug: Ensifentrine
Study Phase: Phase 3
A Randomized, Double-blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of Mono and Combination Therapy With Monoclonal Antibodies in Participants With Mild to Moderate COVID-19 Illness (BLAZE-4)
A Randomized, Double-blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of Mono and Combination Therapy With Monoclonal Antibodies in Participants With Mild to Moderate COVID-19 Illness (BLAZE-4)
Enrollment Status: Completed
Publish Date: July 01, 2022
Intervention Type: Drug
Study Drugs: Bamlanivimab, Etesevimab, LY3853113 Anti-COVID-19 Antibody, VIR-7831 Anti-COVID-19 Antibody
Study Phase: Phase 2
Blood Sample Collection in Subjects With Pulmonary Nodules or CT Suspicion of Lung Cancer or Pathologically Diagnosed Lung Cancer
Blood Sample Collection in Subjects With Pulmonary Nodules or CT Suspicion of Lung Cancer or Pathologically Diagnosed Lung Cancer
Enrollment Status: Completed
Publish Date: February 15, 2021
Intervention Type: Other
2016-11: Blood Sample Collection in Subjects Participating in a Lung Cancer Screening Program
2016-11: Blood Sample Collection in Subjects Participating in a Lung Cancer Screening Program
Enrollment Status: Completed
Publish Date: February 15, 2021
Intervention Type: Other
View 8 Less Clinical Trials

5 Total Publications

Effect of Subcutaneous Casirivimab and Imdevimab Antibody Combination vs Placebo on Development of Symptomatic COVID-19 in Early Asymptomatic SARS-CoV-2 Infection: A Randomized Clinical Trial.
Effect of Subcutaneous Casirivimab and Imdevimab Antibody Combination vs Placebo on Development of Symptomatic COVID-19 in Early Asymptomatic SARS-CoV-2 Infection: A Randomized Clinical Trial.
Journal: JAMA
Published: January 14, 2022
Similar Doctors
Naresh M. Punjabi
Expertise in
5
conditions
Dr. Naresh M. Punjabi
Pulmonary Medicine | Sleep Medicine | Intensive Care Medicine
Expertise in
5
conditions
Dr. Naresh M. Punjabi
Pulmonary Medicine | Sleep Medicine | Intensive Care Medicine

University Of Miami

900 Nw 17th St, Ableh/bpei, 
Miami, FL 
 (14.9 miles away)
305-243-6857
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Naresh Punjabi is a Pulmonary Medicine specialist and a Sleep Medicine provider in Miami, Florida. Dr. Punjabi is highly rated in 5 conditions, according to our data. His top areas of expertise are Obstructive Sleep Apnea, Cerebral Hypoxia, Central Sleep Apnea, and Restless Legs Syndrome. Dr. Punjabi is currently accepting new patients.

Expertise in
8
conditions
Dr. Jeremy I. Tabak
Pulmonary Medicine | Intensive Care Medicine | Sleep Medicine
Expertise in
8
conditions
Dr. Jeremy I. Tabak
Pulmonary Medicine | Intensive Care Medicine | Sleep Medicine

Pulmonary Physicians Of South Florida LLC

8900 N Kendall Dr, 
Miami, FL 
 (4.1 miles away)
786-596-1960
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Jeremy Tabak is a Pulmonary Medicine specialist and an Intensive Care Medicine provider in Miami, Florida. Dr. Tabak is highly rated in 8 conditions, according to our data. His top areas of expertise are Obstructive Sleep Apnea, Bronchiectasis, Hospital-Acquired Pneumonia, and Atypical Pneumonia. Dr. Tabak is currently accepting new patients.

Anas Hadeh
Expertise in
23
conditions
Dr. Anas Hadeh
Pulmonary Medicine | Sleep Medicine
Expertise in
23
conditions
Dr. Anas Hadeh
Pulmonary Medicine | Sleep Medicine

Egil And Pauline Braathen Center/Maroone Cancer Center

2950 Cleveland Clinic Boulevard, 
Weston, FL 
 (29.4 miles away)
877-463-2010
Languages Spoken:
English, Arabic, French
See accepted insurances
Offers Telehealth

Anas Hadeh is a Pulmonary Medicine specialist and a Sleep Medicine provider in Weston, Florida. Dr. Hadeh is highly rated in 23 conditions, according to our data. His top areas of expertise are Obstructive Sleep Apnea, Bronchiectasis, Lung Metastases, Laminectomy, and Endoscopy.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Krainson's expertise for a condition
ConditionClose
        View All 8 Experienced Conditions
        Want to save this doctor for later?
        Sign Up
        Is this your doctor?
        Find A Second Opinion
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile